FGFR3-overexpressing cells are resistant to dexamethasone because of Bcl-xL up-regulation.
(A) Western blot analysis of high- and low-expressing FGFR3 clones. (B) Treatment of high and low FGFR3-transduced cells with dexamethasone rescued with IL-6 and analyzed using Annexin V assay kit at 72 hours after treatment. This demonstrates a correlation between FGFR3 and Bcl-xL levels and dexamethasone resistance. (C) Western blot analysis of B9-TD following treatment with control and antisense oligonucleotides demonstrates successful down-regulation of Bcl-xL. (D) B9MINV, B9-WT, and B9-TD cells treated with various concentrations of dexamethasone following Bcl-xL antisense treatment and analyzed using Annexin V assay kit 72 hours after treatment. The protective effect of FGFR3 expression is abrogated.
